Nearly one million Americans have melanoma and 9,940 will die of the disease in 2015. With poor patient outcomes and no known cure for metastatic melanoma, the unmet need for effective therapies is significant.
Our lead product, SRX-1177, creates a new class of melanoma therapy, combining a novel peptide with a commercially available radioisotope into an injectable drug. Similar radiotherapies for other cancers are effective in up to 75% of patients.
SolaranRx is developing a platform of therapies and companion imaging agents for metastatic melanoma, representing a game changer for both clinicians and patients.